Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1427

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 9A
Chunk 1427
---
 prior to the 150th calendar day after the date of the Agreement.

Subject to the terms
of the Agreement, the Company will be required to pay certain liquidated damages if the shares underlying the New Warrants are not filed
within the ninety (90) period, as more fully described in the Agreement.

The Company further agreed
that until sixty (60) days after the closing date of the warrant exercise, it will not (other than in connection with limited enumerated
exceptions) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common
stock equivalents or file any registration statement or any amendment or supplement (other than the registration statement registering
the shares underlying the Replacement Warrants).

In connection with the
transactions contemplated in the Agreement, the Company agreed to pay its placement agent, Maxim Group, LLC (the “Agent”)
the following compensation, (i) a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated
by the Agreement, and (ii) legal fees and out-of-pocket expenses of $15,000.

May 2024 Public Offering

On May 17, 2024,
the Company closed a public offering pursuant to which it sold an aggregate of: (i) 306,250 shares
of common stock and accompanying Class A warrants to purchase up to 306,250 shares
of common stock and Class B warrants to purchase up to 306,250 shares
of common stock, at a combined public offering price of $4.64
per share and accompanying warrants; and (ii) in lieu of common stock, pre-funded warrants to purchase 706,250 shares
of common stock and accompanying Class A warrants to purchase up to 706,250
shares of common stock and Class B warrants to purchase up to 706,250
shares of common stock, at a combined public offering price of $0.4.63 per pre-funded warrant and accompanying warrants, which is
equal to the public offering price per share of common stock, and accompanying warrants less the $0.001 per share exercise price of
each such pre-funded warrant.

All pre-funded
warrants issued in the offering were exercised in the quarter ended June 30, 2024. The Class A
and Class B warrants each have an exercise price of $4.64 per
share, are immediately exercisable, and, in the case of Class A warrants